Alnylam and regeneron report promising data from ongoing phase 1 study of aln-hsd in nash patients and healthy volunteers

Cambridge, mass. & tarrytown, n.y.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny) and regeneron pharmaceuticals (nasdaq: regn) announced today preliminary phase 1 data supporting the clinical advancement of aln-hsd, an investigational rnai therapeutic targeting hsd17b13 in development for the treatment of nonalcoholic steatohepatitis (nash). after single-dose evaluation in healthy adult volunteers (part a), multiple doses of aln-hsd are being studied in adult patients with nash
REGN Ratings Summary
REGN Quant Ranking